NCT06113302进行中（未招募）2 期
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
研究概览
简要总结
To learn if luspatercept is more effective in helping to reduce the number of blood transfusions needed by patients with LR-MDS.
详细描述
Objectives:
Primary Objectives:
- To assess the clinical activity and safety of luspatercept in patients with transfusion independent lower risk MDS
- To assess the clinical activity and safety of luspatercept in patients with transfusion dependent lower risk MDS
- To study the effects on hematopoeisis of luspatercept in patients treated on this study
Secondary Objectives:
- To assess the duration of response of patients with treated with luspatercept in this study
- To assess the overall survival and time to transformation of patients with treated with luspatercept in this study
- To assess transfusion free survival period in patients that were transfusion independent treated with luspatercept in this study
- To measure trends in neutrophil and platelet counts in patients treated in this study
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years; as MDS there is no significant experience with luspatercept in pediatric patients
- •Cohorts #1 and #2: Diagnosis of MDS according to WHO 2023 criteria (5) and with low or int-1 risk by IPSS or a score of ≤ 3.5 by IPSS-R.(3, 22)
- •Cohort #2: Patient defined as transfusion dependent by documentation of receiving at least 2 units of packed red blood cells (PRBCs) for a hemoglobin of less than 8.0 g/dL during an 8-week period prior to study enrollment.
- •Cohort #1: Patients with symptomatic anemia that are transfusion independent defined as not requiring a transfusion for a hemoglobin of less than 8.0 g/dL during an 8-week period prior to study enrollment.
- •MDS patients with either a platelet count of ≤100 K/uL and/or ANC of ≤1.8 K/uL
- •Patient must have signed an informed consent and is willing to participate in the study.
- •Adequate hepatic function with total bilirubin ≤3 x ULN, AST or ALT ≤3xULN.
- •Serum creatinine clearance ≥40mL/min and no end/stage renal disease (using Cockcroft-Gault).
- •ECOG performance status </=2.
排除标准
- •Active infection not adequately responding to appropriate antibiotics.
- •Prior treatment with luspatercept or sotarcetept
- •Female patients who are pregnant or lactating.
- •Patients with reproductive potential who are unwilling to following contraception requirements (including condom use for males with sexual partners, and for females: prescription oral contraceptives [birth control pills], contraceptive injections, intrauterine devices [IUD], double-barrier method [spermicidal jelly or foam with condoms or diaphragm], contraceptive patch, or surgical sterilization) throughout the study. Reproductive potential is defined as no previous surgical sterilization or females that are not post-menopausal for 12 months.
- •Female patients with reproductive potential who do not have a negative urine or blood beta-human chorionic gonadotropin (beta HCG) pregnancy test at screening.
- •History of an active malignancy within the past 2 years prior to study entry, with the exception of: a. Adequately treated in situ carcinoma of the cervix uteri b. Adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin or any other malignancy with a life expectancy of more than 2 years.
- •Patients receiving any other concurrent investigational agent or chemotherapy, radiotherapy, or immunotherapy (within 14 days of initiating study treatment).
研究组 & 干预措施
Cohort 1
Experimental
Participants with lower risk MDS patients who have symptomatic anemia that are transfusion independent (TI). Participants will be asked to come to the study clinic weekly for the first 3 weeks and then 1 time every 3 weeks after that to have tests and procedures (such as physical exams and blood draws). Luspatercept will be administered once every 3 weeks.
干预措施: Luspatercept (Drug)
Cohort 2
Experimental
Participants with lower risk MDS that are transfusion dependent (TD). Participants will be asked to come to the study clinic weekly for the first 3 weeks and then 1 time every 3 weeks after that to have tests and procedures (such as physical exams and blood draws). Luspatercept will be administered once every 3 weeks.
干预措施: Luspatercept (Drug)
结局指标
主要结局
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
时间窗: through study completion; an average 1 year.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on PlateletsInhibition on Platelet AggregationNCT01744288AstraZeneca258
招募中
不适用
Clinical Observation of Luspatercept in Treatment of Chinese Adult β-thalassaemia Patients With TD β-thalassemiaEffect of DrugNCT06164821Hematology department of the 920th hospital10
已完成
不适用
A Prospective Randomized Study on the Clinical Benefits of OrthoPAT DrainsSpine DeformityNCT02286102Hospital for Special Surgery, New York70
进行中（未招募）
3 期
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome ParticipantsMyelodysplastic SyndromesNCT06045689Bristol-Myers Squibb106
已完成
不适用
Blood Transfusions and Immune ResponseInfection After TransfusionTransfusion-related Immunomodulation ReactionCytokine StormSurgeryNCT02020525Aretaieion University Hospital58